|Bid||5.48 x 2200|
|Ask||6.40 x 800|
|Day's Range||5.50 - 5.96|
|52 Week Range||4.82 - 14.00|
|Beta (3Y Monthly)||1.38|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 7, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||16.09|
If you own shares in CymaBay Therapeutics, Inc. (NASDAQ:CBAY) then it's worth thinking about how it contributes to the...
Given the uncertain economic climate, investors are looking for sectors of the market that will provide refuge. Many analysts are pointing to the healthcare space. While the healthcare segment of the S&P 500 is down 2% over the last month, analysts believe that this sector contains compelling investment opportunities. Investors looking to break into the space don’t have to spend a lot of money to do so. With the help of analysts, we found 3 bargain healthcare stocks under $10 that appear poised for long-term growth. CymaBay Therapeutics Inc. (CBAY)CymaBay develops and commercializes therapies used to treat patients with liver and other chronic diseases. Its most advanced clinical candidate is the seladelpar drug that could be used to treat primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH), or autoimmune liver diseases. The biopharma stock is currently trading at $5.83, with analysts saying share prices have the potential to keep going up. Coming on the heels of its second quarter earnings release, the company looks strong. CBAY has made a significant investment in the development of new and existing treatments. According to the August 7 release, research and development spending increased from $14.4 million in the year-ago quarter to $21.1 million. Management pointed out that the investment in research and development already appears to be paying off. Data from CBAY’s paired liver biopsy study of seladelpar for NASH shows a favorable safety and tolerability profile at all doses. Not to mention the FDA accepted an Investigational New Drug (IND) application to begin a Phase 2 clinical study for seladelpar use in treating primary sclerosing cholangitis (PSC), a chronic cholestatic liver disease that causes diffuse inflammation and fibrosis of the bile ducts. Currently, there aren’t any FDA-approved treatments for PSC on the market. President and CEO Sujal Shah said, “In the second quarter of 2019, we made significant progress advancing the development of seladelpar for PBC and NASH and began activities to further diversify development into PSC. Enrollment in our ENHANCE Phase 3 registration study in PBC, expected to be completed by year-end, continued on track during the quarter. Topline 12-week results from our 52-week, dose-ranging Phase 2b study in NASH showed clinically meaningful reductions in multiple biomarkers of inflammation and liver injury despite minimal reductions in total liver fat.” Ed Arce, a four-star analyst according to TipRanks, agrees that the investment will bolster CBAY’s long-term growth narrative. On August 8, he reiterated his Buy rating and $12 price target. The H.C. Wainwright analyst believes share prices could soar by 106% over the next twelve months. The rest of the Street is bullish on this healthcare stock. CBAY has a ‘Strong Buy’ analyst consensus and a $14 average price target, suggesting 137% upside potential. Karyopharm Therapeutics Inc. (KPTI)Karyopharm Therapeutics is a clinical stage pharmaceutical company that develops treatments for cancer and other diseases. Its drugs directly target nuclear transport and related targets. KPTI is trading at $8.86, with some analysts saying more upside is set to follow. On July 3, KPTI’s XPOVIO received accelerated approval from the FDA. The drug was approved for the combined use with dexamethasone to treat adult patients who have relapsed or refractory multiple myeloma and have already received at least four therapies. After the approval, XPOVIO became commercially available in the U.S. on July 9. Management stated, “Early prescribing trends are encouraging with robust demand from both academic and community-based physicians throughout the U.S. with early prescriptions being filled for patients with Medicare and commercial insurance coverage.” KPTI has also made substantial efforts to expand its reach. It submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for conditional approval of XPOVIO’s combined use with dexamethasone. Not to mention its Pivotal Phase 3 BOSTON study is in progress testing XPOVIO’s combined use with proteasome inhibitor Velcade (bortezomib) and low dose dexamethasone (SVd). The treatment would be used for patients with multiple myeloma that have only received one to three therapies.Edward White, a five-star analyst, believes XPOVIO’s success will fuel KPTI’s continued growth. “We base our $32 price target on probability-adjusted revenue forecasts for XPOVIO (selinexor). We use a net present value of $7.91 for our revenue forecast through 2026, that includes the approval of Xpovio in penta-refractory multiple myeloma, a 40% probability of success (POS) for XPOVIO in combination treatment for multiple myeloma, a 30% POS for 25% POS for XPOVIO in solid tumors,” he said. On August 6, the H.C. Wainwright analyst reiterated his Buy rating and $32 price target, implying 261% upside. One-star analyst, Eric Joseph said, “Our doctor survey supports a strong XPOVIO launch and long-term outlook.” On July 23, the J.P. Morgan analyst upgraded KPTI to a Buy and raised the price target from $8 to $16. He believes share prices could rise 81% over the next twelve months. KPTI has a ‘Strong Buy’ analyst consensus and a $20 average price target, suggesting 128% upside potential. Syndax Pharmaceuticals, Inc. (SNDX)The last healthcare stock on our list also develops treatments for cancer patients. With Syndax currently trading at $9.89, many analysts are saying now’s the time to get on board.On August 7, the company reported a second quarter net loss of $15 million or $0.47 per share. However, its loss narrowed from $18.4 million or $0.74 per share in the year-ago quarter. SNDX was also able to cut general and administrative costs from $4.5 million in the prior-year quarter to $3.5 million. The company’s most promising candidate is its entinostat treatment for breast cancer. In May 2019, E2112 trial passed its fourth interim overall survival (OS) analysis. The endocrine-based therapy could be a catalyst for SNDX, with results from the study expected to be released in the fourth quarter of 2019. Investors got another reason to be excited in July when the FDA approved the company’s IND application to start a Phase 1/2 trial for SNDX-5613, a highly selective Menin inhibitor to treat relapsed or refractory acute leukemias. SNDX is also researching drugs to treat chronic graft versus host disease (cGVHD). White, who also covers SNDX, believes that the company’s entinostat drug has the potential to fuel continued growth. On August 8, the analyst reiterated his Buy rating and $16 price target, suggesting 62% upside potential. “We base our $16 price target on probability-adjusted revenue forecasts for entinostat in combination treatment for advanced HR+, HER2- breast cancer. We use the net present value of our revenue forecast through 2027, apply a 40% POS for HR+, HER2- breast cancer, with a 3x price/sales multiple,” he said. Four-star analyst, Harshita Polishetty, agrees that its breast cancer drug is especially promising. “Taken as a whole, we believe the next preplanned overall surival (OS) interim analysis for E2112, scheduled for 4Q19, is a very important catalyst for the company. Overall, we remain focused on the potential of entinostat in HR+, HER2- breast cancer,” the B.Riley FBR analyst said. On August 8, he reiterated his Buy rating and $26 price target, implying 163% upside potential. Polishetty has a 62% success rate and gets an average return of 27% per rating. SNDX has a ‘Strong Buy’ analyst consensus and an average price target of $19, indicating 95% upside. Discover the Analysts’ Top-Rated Stocks right now
NEWARK, Calif., Aug. 07, 2019 -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other.
CymaBay Therapeutics, Inc. (CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced the addition of Ms. Janet Dorling as Chief Commercial Officer effective today. "We are very pleased to welcome Janet to the CymaBay team at this pivotal time, as we pursue regulatory approval of our lead product candidate, seladelpar, for the treatment of primary biliary cholangitis (PBC) and as we continue to advance development in additional indications," said Sujal Shah, Chief Executive Officer of CymaBay.
NEWARK, Calif., July 31, 2019 -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other.
CymaBay Therapeutics, Inc. (CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced FDA clearance of the company’s Investigational New Drug Application (IND) for seladelpar to treat primary sclerosing cholangitis (PSC). The company intends to initiate a Phase 2 study to evaluate the safety, tolerability, and efficacy of seladelpar in patients with PSC in the third quarter. PSC is a rare, chronic cholestatic liver disease that is characterized by diffuse inflammation and fibrosis of the bile ducts.
For a week now, the market has been seeing trading range action with a generally positive bias. That is continuing Monday as market players look ahead to the Federal Reserve interest rate decision on Wednesday afternoon.
Looking deeper into a target of a CRISPR deal, a fundraising for more-targeted approach to mental health therapies and more in our Health Care Digest.
CymaBay Therapeutics, Inc. (CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced that Sujal Shah, President and Chief Executive Officer, will participate in a fireside chat at Raymond James Life Sciences and MedTech Conference on Wednesday, June 19, 2019 at 8:00 a.m. ET (5:00 a.m. PT) at the Lotte New York Palace in New York City. A live audio webcast of the presentation can be accessed through the Investors section of the CymaBay Therapeutics corporate website at http://ir.cymabay.com/events. Seladelpar is a potent, selective, orally active PPARδ agonist that is in development for the treatment of the liver diseases PBC and NASH.
CymaBay Therapeutics (CBAY) is currently enrolling patients in its Phase 3 registrational trial, ENHANCE, to evaluate the use of its investigational PPARδ (peroxisome proliferator-activated receptor delta) agonist, seladelpar, in PBC (primary biliary cholangitis).
CymaBay Therapeutics (CBAY) closed at $6.17 on June 12, 1.98% higher than its previous close, 28.01% above its 52-week low of $4.82, and 58.87% below its 52-week high of $15.
Intercept Pharmaceuticals (ICPT) closed at $80.99 on June 12, 0.90% higher than its previous close, 10.93% above its 52-week low of $73.01, and 39.44% below its 52-week high of $133.74.
This year, CymaBay Therapeutics (CBAY) has fallen 21.60% and Viking Therapeutics (VKTX) has risen 4.31%. While both clinical-stage companies focus on advancing their nonalcoholic steatohepatitis research and development programs, Viking seems to be ahead, considering its successful Phase 2 trials.
While the market driven by short-term sentiment influenced by the accomodative interest rate environment in the US, increasing oil prices and optimism towards the resolution of the trade war with China, many smart money investors kept their cautious approach regarding the current bull run in the first quarter and hedging or reducing many of their […]
The small-cap biotech company released disappointing trial data on Tuesday, triggering a selloff. Raymond James analyst Steven Seedhouse says the stock is now a Strong Buy.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 11) BIOFRONTERA AG/ADR (NASDAQ: BFRA ) BIO-TECHNE Corp ...
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...
Shares of CymaBay Therapeutics Inc. plummeted 43% in premarket trade Tuesday after the biotech said data from an ongoing Phase 2 trial showed patients with nonalcoholic steatohepatitis (NASH) who were treated with investigational drug seladelpar did not show significant reductions in liver fat when compared with those on a placebo. However, treatment with seladelpar did result in a reduction in biomarkers associated with liver injury, the company said. "While the reductions in liver fat were minimal, we remain encouraged by the significant improvements in biochemical markers of liver injury that we observed at week 12," said Pol Boudes, CymaBay's chief medical officer. "The 52-week liver biopsy data will allow us to understand whether the improvement in liver injury markers will translate into histological improvement. The observed improvement in markers of liver injury are consistent with the observed effects of seladelpar in PBC and further support the potential for seladelpar to improve liver health." In NASH, fat builds up in the liver, triggering inflammation and cell injury that can lead to serious complications like cirrhosis, or liver scarring. There have been several trial updates in the NASH space so far this year from companies like Gilead Sciences Inc. and Intercept Pharmaceuticals Inc. , but they have not been promising, according to Jefferies health desk trader Jared Holz. "Investors have not been impressed with current data," he wrote in a note to clients Tuesday morning. Shares of CymaBay Therapeutics Inc. have gained 41% in the year to date through Monday, while the S&P 500 has gained 15%.
CymaBay Therapeutics (NASDAQCBAY) announced results from an ongoing 52-week Phase 2b dose-ranging, paired liver biopsy study of "seladelpar" for the treatment of nonalcoholic steatohepatitis. ...